Treeline Biosciences
PrivateLast Round
Reverse Merger
Jun 8, 2026
Est. Valuation
$2.96B
Total Funding Raised
$1.1B
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Treeline Biosciences is a biotechnology company that develops transformative precision medicines for cancer and other serious conditions through a drug discovery platform integrating mechanistic biology, medicinal chemistry, computational science, and structural biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Treeline Biosciences Comparables
Compare Treeline Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Odyssey Therapeutics | 89% | |
| Xaira Therapeutics | 88% | |
| Valo Health | 88% |
For institutional investors. Book with your work email.
Treeline Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Reverse Merger | Jun 8, 2026 | ||||
| Series A | Sep 3, 2025 | ||||
| Series A | Oct 17, 2024 | ||||
| Series A | Oct 17, 2022 | ||||
| Series A | Apr 9, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Treeline Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A |
| Soleus Capital | Series A |
| Access Industries | Series A |
| Kohlberg Kravis Roberts | Series A |
| Boxer Capital | Series A |
| GV | Series A |
| Ajax Health | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 62% MoM, reaching 8.2K.
- Jun 18, 2026
Monthly visitors increased 59% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 3, 2026
Treeline Biosciences, Inc. is developing a Phase I TLN-121 combination trial with Roche to assess TLN-121 with glofitamab and mosunetuzumab in patients with B-cell lymphomas, including separate diffuse large B-cell lymphoma cohorts, and plans to start combination dosing in Q4 '26.
- partners_withSep 3, 2026
Treeline Biosciences, Inc. partners with Roche on a Phase 1 study evaluating TLN-121 with glofitamab and mosunetuzumab in patients with B-cell lymphomas, with treatment planned to begin in Q4 '26.
- is_developingSep 2, 2026
Treeline Biosciences, Inc. collaborates with Roche to develop a combination of TLN-121, Columvi and Lunsumio for B-cell lymphomas, with Treeline Biosciences, Inc. financing and conducting the phase 1 study and planning to begin treatment in Q4 '26.
For institutional investors. Book with your work email.
Treeline Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Treeline Biosciences's valuation, stock price, and market status.
Is Treeline Biosciences a public or private company?
Treeline Biosciences is a private company.
What is the current stock price of Treeline Biosciences?
Treeline Biosciences is a private company, so its shares have no public market price. Caplight tracks Treeline Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Treeline Biosciences worth (valuation)?
Treeline Biosciences's valuation is estimated at $3.0B based on funding round data.
Can I buy Treeline Biosciences stock?
Treeline Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Treeline Biosciences's last funding round?
Treeline Biosciences's most recent funding round was Reverse Merger on June 8, 2026.
Who are the main investors in Treeline Biosciences?
Key investors in Treeline Biosciences include Kohlberg Kravis Roberts, GV, OrbiMed, ARCH Venture Partners.
Will Treeline Biosciences IPO soon?
No public IPO plans have been announced for Treeline Biosciences.
How can I track Treeline Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Treeline Biosciences's shares on secondary markets.